Transcript of Idelalisib: Analysis of Pivotal Data Jeff Sharman M.D. Willamette Valley Cancer Institute Eugene...
- Slide 1
- Idelalisib: Analysis of Pivotal Data Jeff Sharman M.D.
Willamette Valley Cancer Institute Eugene Oregon US Oncology
Research
- Slide 2
- Disclosures Consulting: Gilead, Pharmacyclics, Celgene Research
Funding: Gilead, Pharmacyclics, Genentech, Seattle Genetics,
Celgene, Novartis, TG Therapeutics Honoraria: Gilead,
Genentech
- Slide 3
- US Labeled Indications Indications referenced from:
https://www.zydelig.com/hcp/
- Slide 4
- StrategyORRPFS Byrd JCO 2001 Intensification 3x weekly45%10
Months OBrien JCO 2001 Escalation 500-2250 mg/m236%8 Months
Monotherapy Publications
- Slide 5
- Patterns of Care ConnectUS OncologyConnectUS Oncology
FCR/PCR3217184 R-Benda27333843 Rituximab14211824 Flu +/-
Ritux10513- Chlorambucil753- First Line Therapy Second Line Therapy
1)Sharman et al ASH 2011 2)Market Connect / McKesson Specialty
Health
- Slide 6
- Single agent idelalisib 101-02 Study Brown et al Blood
2014
- Slide 7
- Single agent idelalisib 101-02 Study
- Slide 8
- Idelalisib Combination 101-07 Study Sharman et al ASH 2011
- Slide 9
- Idelalisib Combination 101-07 Study Sharman et al ASH 2011
- Slide 10
- CLL Registration Study
- Slide 11
- Healthy Volunteer Trials Dose-ranging Metabolism Hematologic
Cancer Trials Single-agent (101-02 Study) Combination (101-07
Study) Combination (101-08 Study) Full Development 2011-2016 Early
Development 2008-2010 Refractory iNHL Phase 2 single-agent (101-09
Study) Previously treated iNHL Phase 3 combination immuno or
chemoimmunotherapy 124 Study: R GS-1101 125 Study: BR GS-1101 iNHL
Accelerated Approval iNHL Full Approval Previously treated CLL
Phase 3 combination with CD-20 mAb 116/117 Study: R GS-1101 119
Study: Ofa GS-1101 CLL Full Approval Additional studies lymphoid
malignancies Exploration & Indication Expansion Previously
treated CLL Phase 3 combination with chemoimmunotherapy 115 Study:
BR GS-1101 Study Context
- Slide 12
- Slide 13
- in patients for whom rituximab alone would be considered
appropriate therapy due to other comorbidities
CharacteristicPercentageMedian Age > 6578%71 Cr Clearance <
6040%64 ml/min Grade 3 Marrow35% CIRS > 685%8
- Slide 14
- Treatment Disposition Coutre et al ASCO 2014
- Slide 15
- Slide 16
- Outcomes Coutre et al ASCO 2014
- Slide 17
- Black Box - Grade 5 Toxicity Grade 5 Hepatotoxicity 1/1192 =
0.1% Diarrhea 1/1192 =